Patent application serial number 464018 has not been assigned to a company or institution.
The following quote was obtained by the news editors from the background information supplied by the inventors: "Hypoglycemic agents may be used in the treatment of both Type I and Type II diabetes to lower glucose concentration in blood. Insulinotropic peptides have been implicated as possible therapeutic agents for the treatment of diabetes. Insulinotropic peptides include incretin hormones such as, but are not limited to, gastric inhibitory peptide (GIP) and glucagon like peptide-1 (GLP-1) as well as fragments, variants, and conjugates thereof. Insulinotropic peptides also include exendin 3 and exendin 4. GLP-1 is a 30 amino acid long incretin hormone secreted by the L-cells in the intestine. GLP-1 has been shown to stimulate insulin secretion in a physiological and glucose-dependent manner, decrease glucagon secretion, inhibit gastric emptying, decrease appetite, and stimulate proliferation of .beta.-cells.
"Insulin and insulinotropic peptides may be administered via subcutaneous injection, such as with a needle containing device, for example, a pen injector, and/or syringe. Patients may need to inject several times a day to control blood glucose, which can be burdensome as well as painful. Thus, there is a need for methods of administering hypoglycemic agents less frequently and by methods that will minimize such burdensome regimens as well as site injection pain."
In addition to the background information obtained for this patent application, NewsRx journalists also obtained the inventors' summary information for this patent application: "In one embodiment of the present invention, methods are provided for administering a GLP-1 agonist composition comprising at least one polypeptide to a patient in need thereof, comprising the step of injecting the GLP-1 agonist composition via an injection device comprising a tube having a gauge of about 28 or greater, wherein said polypeptide is administered no more than once daily. The polypeptide may be, but is not limited to, GLP-1 or a fragment, variant, and/or conjugate thereof. Certain embodiments of a GLP-1 or a fragment, variant, or conjugate thereof comprise human serum albumin. Human serum albumin, variants and/or fragments thereof, may be conjugated to a GLP-1 or fragment or variant thereof. Human serum albumin may be conjugated through a chemical linker, including but not limited to naturally occurring or engineered disulfide bonds, or by genetic fusion to GLP-1, or a fragment or variant thereof.
"In another aspect of the present invention, methods are provided for administering a hypoglycemic agent comprising at least one polypeptide to a patient in need thereof, comprising the step of injecting the hypoglycemic agent via an injection device comprising a tube having a gauge of about 28 or greater, wherein said polypeptide is administered no more than once daily.
"In another aspect of the present invention, methods are provided for treating or preventing a disease in a mammal in need thereof comprising administering a composition comprising at least one polypeptide having GLP-1 agonist activity once weekly, wherein the composition comprises about 0.25 mg to about 104 mg of at least one polypeptide having GLP-1 activity. The mammal may suffer from one or more of the following diseases: Type I diabetes, Type II diabetes, obesity and hyperglycemia.
BRIEF DESCRIPTION OF THE DRAWINGS
"FIG. 1: A device for delivery of lyophilized hypoglycemic agent and/or GLP-1 agonist
"FIG. 2: SEQ ID NO:1 which comprises two tandemly oriented GLP-1(7-36)(A8G) fused to the N-Terminus of human serum albumin."
URL and more information on this patent application, see: Bush, Mark A.; O'Neill,
Keywords for this news article include: Patents, Diabetes, Peptides, Treatment, Proteomics, Amino Acids, Therapeutics, Serum Albumin, Blood Proteins, Acute-Phase Proteins.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
Most Popular Stories
- Hezbollah Chief's Assassination Claimed by Sunni Group
- SpaceX's Satellite Launch Is 'Game-Changer'
- Allstate Seeks to Invest in Minority Firms
- U.S. Growth Stayed Steady During Shutdown, Fed Says
- Newtown Massacre Heard on 911 Recordings
- Climate Change Early Warning System Urged
- Latin Music Conference Turns 25
- New Home Sales Shoot up 25 Percent in October
- Reid Confident Congress to Pass Immigration Bill
- Liberty Power Gets Minority Business Nod